+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Jiangsu Hengrui Medicine Co Ltd (600276) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 61 Pages
  • June 2024
  • GlobalData
  • ID: 4418478
Jiangsu Hengrui Medicine Co Ltd (600276) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Jiangsu Hengrui Medicine Co Ltd - Key Facts
  • Jiangsu Hengrui Medicine Co Ltd - Key Employees
  • Jiangsu Hengrui Medicine Co Ltd - Major Products and Services
  • Jiangsu Hengrui Medicine Co Ltd - History
  • Jiangsu Hengrui Medicine Co Ltd - Company Statement
  • Jiangsu Hengrui Medicine Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Jiangsu Hengrui Medicine Co Ltd - Business Description
  • Product Category: Anaesthetization
  • Performance
  • Product Category: Antitumor
  • Performance
  • Product Category: Contrast Agent
  • Performance
  • Product Category: Other
  • Performance
  • Geographical Segment: Domestic
  • Performance
  • Geographical Segment: Foreign
  • Performance
  • R&D Overview
  • Jiangsu Hengrui Medicine Co Ltd - Corporate Strategy
  • Jiangsu Hengrui Medicine Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Jiangsu Hengrui Medicine Co Ltd - Strengths
  • Jiangsu Hengrui Medicine Co Ltd - Weaknesses
  • Jiangsu Hengrui Medicine Co Ltd - Opportunities
  • Jiangsu Hengrui Medicine Co Ltd - Threats
  • Jiangsu Hengrui Medicine Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Jiangsu Hengrui Medicine Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 21, 2024: Innovation strength is recognized again! Hengrui ranks among the top 10 in the global pharmaceutical invention index for the first time, ranking first among Chinese pharmaceutical companies
  • Apr 12, 2024: Hengrui Pharmaceutical’s Three Innovative Drugs HRS-9231 Injection, SHR-4597 Inhalation and SHR-2173 Injection Were Approved for Clinical Trials
  • Nov 17, 2023: On November 16, Hengrui Medicine's 2023 R&D Day was successfully held in Pudong, Shanghai. With the theme of "Deepening and Expanding, Opening and Gathering Strength", the event
  • Oct 26, 2023: Medically driven, academic innovation|The 2023 ESMO Conference concluded successfully, Hengrui Medicine once again delivered excellent answers with 7 oral reports
  • Oct 10, 2023: Hengrui Medicine’s 35 research results on 13 innovative anti-tumor drugs will appear on the international stage
  • Jun 29, 2023: Hengrui Medicine once again tops the list of China's top 100 chemical pharmaceutical companies
  • Jun 25, 2023: Hengrui Medicine unveils the latest research results of two innovative hypoglycemic drugs
  • Jan 10, 2023: The list of candidates for the new board of directors of Hengrui Medicine was announced, and the chief strategy officer appeared
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Jiangsu Hengrui Medicine Co Ltd, Key Facts
  • Jiangsu Hengrui Medicine Co Ltd, Key Employees
  • Jiangsu Hengrui Medicine Co Ltd, Major Products and Services
  • Jiangsu Hengrui Medicine Co Ltd, History
  • Jiangsu Hengrui Medicine Co Ltd, Subsidiaries
  • Jiangsu Hengrui Medicine Co Ltd, Joint Venture
  • Jiangsu Hengrui Medicine Co Ltd, Key Competitors
  • Jiangsu Hengrui Medicine Co Ltd, Ratios based on current share price
  • Jiangsu Hengrui Medicine Co Ltd, Annual Ratios
  • Jiangsu Hengrui Medicine Co Ltd, Interim Ratios
  • Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Jiangsu Hengrui Medicine Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Jiangsu Hengrui Medicine Co Ltd, Performance Chart (2019 - 2023)
  • Jiangsu Hengrui Medicine Co Ltd, Ratio Charts
  • Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Chongqing Laimei Pharmaceutical Co Ltd
  • Sino Biopharmaceutical Ltd
  • Sundia MediTech Co Ltd
  • Akeso Inc
  • Skystar Bio-Pharmaceutical Co
  • Sinopharm Group Co Ltd